Skip to main content
DTIL
NASDAQ Life Sciences

Precision BioSciences Launches Stock and Pre-Funded Warrant Offering on Heels of Hepatitis B Data

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$8.5
Mkt Cap
$226.838M
52W Low
$3.53
52W High
$9.62
52W Position info
141% above low
Off High info
12% below high
Rel. Volume info
1.6× avg
Market data snapshot near publication time

DTIL has more than doubled off its 52-week low of $3.53.

Summary

Precision BioSciences is offering common stock and pre-funded warrants under its January 7, 2026 shelf, with size and pricing left blank in this free writing prospectus. Proceeds fund PBGENE-HBV and PBGENE-DMD development and working capital.

Updates

  1. · BusinessWire — Precision priced the offering at $7.75 per share for 10,235,077 shares plus pre-funded warrants for 5,893,964 shares, raising about $125M gross, expected to close November 6, 2026.


Key Events · Financing and Capital Events · DTIL

  • Stock and Pre-Funded Warrant Offering Launched

    Precision is offering common stock and, in lieu of shares to certain investors, pre-funded warrants to purchase up to a stated number of shares, under its January 7, 2026 S-3 shelf. The share count and price are left blank in this free writing prospectus.

  • Pre-Funded Warrant Terms Set

    Each pre-funded warrant costs the offering price per share minus $0.000005, the exercise price. Warrants never expire, allow cashless exercise, and carry a 4.99% (or 9.99% at the holder's option) ownership blocker adjustable up to 19.99%.

  • Proceeds Earmarked for Two Gene Editing Programs

    Net proceeds, amount undisclosed, will fund continued research and development of PBGENE-HBV and PBGENE-DMD plus working capital and general corporate purposes.

  • Offering Timed to Hepatitis B Data

    The offering follows same-day disclosure of Phase 1 ELIMINATE-B data: undetectable pgRNA in 100% of evaluable patients at the 0.4 mg/kg go-forward dose, with Phase 2 dosing expected to begin in the first quarter of 2027.


Analysis · DTIL · Life Sciences

Precision is raising capital through a stock and pre-funded warrant offering under its existing January 7, 2026 shelf, timed to same-day PBGENE-HBV Phase 1 data showing undetectable pgRNA in 100% of evaluable patients at the 0.4 mg/kg go-forward dose. The filing leaves the size, price per share, and net proceeds blank, so the dilution cannot be quantified yet. Proceeds are earmarked for PBGENE-HBV and PBGENE-DMD development plus working capital, extending funding for two clinical programs but at the cost of new shares issued into a stock trading at $8.50. The pre-funded warrants carry a $0.000005 exercise price, no expiration, cashless exercise, and a 4.99%/9.99% ownership blocker adjustable up to 19.99%, so they function as deferred equity rather than priced options.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, DTIL was trading at $8.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $226.8M. The 52-week trading range was $3.53 to $9.62. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

DTIL - Latest Insights

DTIL
Nov 05, 2026, 7:10 AM EST
Source: BusinessWire
Importance Score:
8
Price at Filing: $7.73
Real-time Price: $7.40 info
Change: -$0.330 (-4%) info
Market Cap: $206.724M info
DTIL
Nov 05, 2026, 7:01 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $8.39
Real-time Price: $7.40 info
Change: -$0.990 (-12%) info
Market Cap: $206.724M info
DTIL
Nov 05, 2026, 7:00 AM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $8.57
Real-time Price: $7.40 info
Change: -$1.17 (-14%) info
Market Cap: $206.724M info
DTIL
Nov 05, 2026, 7:00 AM EST
Source: BusinessWire
Importance Score:
8
Price at Filing: $8.39
Real-time Price: $7.40 info
Change: -$0.990 (-12%) info
Market Cap: $206.724M info
DTIL
Nov 03, 2026, 8:58 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $7.33
Real-time Price: $7.40 info
Change: +$0.070 (+0.95%) info
Market Cap: $206.724M info